NVAX

NVAX's FY2025 'turn to profitability' is far less than it looks. Of the $685M in product sales, the MD&A attributes $575.7M to the Canada APA termination and $27.3M to the New Zealand APA termination — roughly $603M of one-time contract-cancellation payments sitting inside the $625M Nuvaxovid line. Strip those out and underlying commercial product sales are only ~$22M plus ~$60M of supply. The $440M net income and $2.58 diluted EPS are therefore a one-time harvest of APA terminations and Sanofi/Takeda licensing milestones, not repeatable earnings power. The tell is the cash flow statement: operating cash flow was -$245M even in this 'profitable' year, cash fell 54.6% to $241M, stockholders' equity is -$128M, and accumulated deficit is -$4.57B. A 3.6x P/E on non-recurring earnings is a mirage, not a value signal.

That said, this is not a melting ice cube either. Near-term liquidity is adequate — current assets of $978M against current liabilities of $460M (a 2.1x current ratio), even if much of that is APA receivables rather than cash. More importantly, the strategic pivot has substance: management is reshaping NVAX from a single-product COVID vaccine maker into a capital-light Matrix-M adjuvant licensor. The January 2026 Pfizer deal ($30M upfront, up to $500M milestones, high-mid-single-digit royalties, 'potential to generate billions'), the Sanofi CLA ($225M of milestones earned in 2025 and positive Phase 1/2 flu-COVID combination data pointing toward Phase 3), Takeda ($41.7M in 2025, up from $0.9M), and the R21/Matrix-M malaria vaccine give genuine, non-dilutive optionality.